Heart failure (HF) constitutes a major health problem worldwide, associated with significant
morbidity and mortality.
1
In addition, long-term outcomes of acute decompensated HF remain poor, with 1-year
mortality reaching up to 40%.
2
Residual congestion and diuretic response represent main predictors of re-admission
and all-cause death in survivors of an acute HF event.
2
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been recently approved to
treat HF with reduced left ventricular ejection fraction,
2
while empagliflozin is also recommended for patients with HF with preserved left
ventricular ejection fraction, regardless of diabetes mellitus status at baseline.
3
However, the efficacy of SGLT-2 inhibitors in patients with acute decompensated HF
remain unknown. Here, we sought to determine the cardiovascular efficacy of this drug
class in the acute HF setting.- Anker SD
- Butler J
- Filippatos G
- Ferreira JP
- Bocchi E
- Böhm M
- Brunner-La Rocca HP
- Choi DJ
- Chopra V
- Chuquiure-Valenzuela E
- Giannetti N
- Gomez-Mesa JE
- Janssens S
- Januzzi JL
- Gonzalez-Juanatey JR
- Merkely B
- Nicholls SJ
- Perrone SV
- Piña IL
- Ponikowski P
- Senni M
- Sim D
- Spinar J
- Squire I
- Taddei S
- Tsutsui H
- Verma S
- Vinereanu D
- Zhang J
- Carson P
- Lam CSP
- Marx N
- Zeller C
- Sattar N
- Jamal W
- Schnaidt S
- Schnee JM
- Brueckmann M
- Pocock SJ
- Zannad F
- Packer M
EMPEROR-Preserved Trial Investigators
Empagliflozin in heart failure with a preserved ejection fraction.
Empagliflozin in heart failure with a preserved ejection fraction.
N Engl J Med. 2021; 385: 1451-1461
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Heart failure.Lancet. 2017; 390: 1981-1995
- Characteristics of acute heart failure hospitalizations based on presenting severity.Circ Heart Fail. 2019; 12 (e005171)
- Empagliflozin in heart failure with a preserved ejection fraction.N Engl J Med. 2021; 385: 1451-1461
- Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).Eur J Heart Fail. 2020; 22: 713-722
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial [published online February 20, 2022]. Nat Med doi:10.1038/s41591-021-01659-1
- SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure.N Engl J Med. 2021; 384: 117-128
Article Info
Publication History
Published online: April 05, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
